Literature DB >> 21734724

Cyclin D as a therapeutic target in cancer.

Elizabeth A Musgrove1, C Elizabeth Caldon, Jane Barraclough, Andrew Stone, Robert L Sutherland.   

Abstract

Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21734724     DOI： 10.1038/nrc3090

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  183 in total

1.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.

Authors:  Zhijiu Zhong; Wen-Shuz Yeow; Chunhua Zou; Richard Wassell; Chenguang Wang; Richard G Pestell; Judy N Quong; Andrew A Quong
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

Authors:  G Siemeister; U Luecking; C Wagner; K Detjen; C Mc Coy; Klaus Bosslet
Journal:  Biomed Pharmacother       Date:  2006-06-23       Impact factor: 6.529

3.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

4.  The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.

Authors:  X Zeng; F Y Shaikh; M K Harrison; A M Adon; A J Trimboli; K A Carroll; N Sharma; C Timmers; L A Chodosh; G Leone; H I Saavedra
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

Review 5.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 6.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

7.  Mouse development and cell proliferation in the absence of D-cyclins.

Authors:  Katarzyna Kozar; Maria A Ciemerych; Vivienne I Rebel; Hirokazu Shigematsu; Agnieszka Zagozdzon; Ewa Sicinska; Yan Geng; Qunyan Yu; Shoumo Bhattacharya; Roderick T Bronson; Koichi Akashi; Piotr Sicinski
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

8.  Cyclin D1 in low-dose radiation-induced adaptive resistance.

Authors:  K M Ahmed; M Fan; D Nantajit; N Cao; J J Li
Journal:  Oncogene       Date:  2008-08-11       Impact factor: 9.867

9.  Distinct proliferative and transcriptional effects of the D-type cyclins in vivo.

Authors:  Lisa K Mullany; Peter White; Eric A Hanse; Christopher J Nelsen; Melissa M Goggin; Joseph E Mullany; Chelsea K Anttila; Linda E Greenbaum; Klaus H Kaestner; Jeffrey H Albrecht
Journal:  Cell Cycle       Date:  2008-05-12       Impact factor: 4.534

10.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.

Authors:  Somaia Elsheikh; Andrew R Green; Mohammed A Aleskandarany; Matthew Grainge; Claire E Paish; Maryou B K Lambros; Jorge S Reis-Filho; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2007-07-26       Impact factor: 4.872
View more
  555 in total

Review 1.  Microenvironmental control of the breast cancer cell cycle.

Authors:  Xun Guo; Yuehan Wu; Helen J Hathaway; Rebecca S Hartley
Journal:  Anat Rec (Hoboken)       Date:  2012-01-24       Impact factor: 2.064

2.  Measuring cell cycle progression kinetics with metabolic labeling and flow cytometry.

Authors:  Helen Fleisig; Judy Wong
Journal:  J Vis Exp       Date:  2012-05-22       Impact factor: 1.355

3.  Modification of the DNA damage response by therapeutic CDK4/6 inhibition.

Authors:  Jeffry L Dean; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

4.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.

Authors:  Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

Review 5.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

6.  Nuclear accumulation of cyclin D1 following long-term fractionated exposures to low-dose ionizing radiation in normal human diploid cells.

Authors:  Tsutomu Shimura; Nobuyuki Hamada; Megumi Sasatani; Kenji Kamiya; Naoki Kunugita
Journal:  Cell Cycle       Date:  2014-02-14       Impact factor: 4.534

7.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 8.  Potential roles of longan flower and seed extracts for anti-cancer.

Authors:  Chih-Cheng Lin; Yuan-Chiang Chung; Chih-Ping Hsu
Journal:  World J Exp Med       Date:  2012-08-20

9.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

Review 10.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.